An overview of the
current data from PsoProtectMe
Current Data
We are committed to sharing data and are delighted to provide open access to summary information from PsoProtectMe. These data are preliminary and include a limited number of participants, so should not be used to inform clinical decision making.
Click here to read our scientific research paper detailing PsoProtect data. A summary of this research can be found on the Psoriasis Association website here.
Our scientific research paper detailing shielding behaviour can be found here. A summary can also be found on the Psoriasis Association website here.
Summary data from PsoProtectMe’s first 3787 participants.
Participants per country (≥10 participants):
| Country | Participants | Country | Participants |
|---|---|---|---|
| Argentina | 79 | Netherlands | 26 |
| Australia | 37 | Norway | 17 |
| Brazil | 30 | Panama | 11 |
| Canada | 52 | Peru | 16 |
| Chile | 216 | Philippines | 56 |
| Denmark | 51 | Poland | 65 |
| Greece | 11 | Portugal | 203 |
| Hong Kong | 18 | Singapore | 13 |
| India | 30 | Spain | 71 |
| Ireland | 57 | Sweden | 39 |
| Italy | 33 | United Kingdom | 2110 |
| Japan | 97 | United States | 276 |
| Malaysia | 10 | Other (<10) | 163 |
Average age: 46 years (range 3-91)
Average BMI: 26.8 kg/m2
Type of psoriasis: 3178 plaque psoriasis, 807 guttate psoriasis, 212 pustular psoriasis, 76 erythrodema
Gender:
Smoking status:
Coexisting psoriatic arthritis:
Type of psoriasis treatment:
Psoriasis severity change during the pandemic:
Have you been diagnosed with or thought you had COVID-19?
Did you go to hospital A&E due to your COVID-19?
Did you stay in hospital due to your COVID-19?
Has your COVID-19 infection got better?